CClinicalTrials.gg
CompletedNCT03305627PAPRACUpdated May 8, 2024

Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy

An interventional study of Short PAP and Extended PAP in Radical Cystectomy, Surgical Site Infection and Urologic Cancer, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cystectomy with urinary diversion (ileal conduit, orthotopic ileal bladder substitute, continent catheterizable pouch) is the best treatment option for patients with muscle-invasive bladder cancer. This intervention is one of the most challenging in urology and has a high rate of postoperative complications including around 30% of postoperative infections.

Perioperative antibiotic prophylaxis (PAP) is widely accepted as a crucial preventive measure to reduce the incidence of surgical site infections (SSI). The rationale for PAP is the reduction of the local bacterial load at the site and time of intervention, and therefore a short duration of PAP of 24 to maximal 48 hours is recommended for all clean to clean-contaminated procedures..

Evidence supporting the optimal duration of PAP for radical cystectomy with urinary diversion is lacking. Based on data extrapolated from abdominal surgery, current guidelines recommend short-term PAP (≤24h) for all clean-contaminated procedures including radical cystectomy.

However, a recent evaluation revealed a significant inter-hospital variability of PAP and showed that extended use (>48h) was common in patients undergoing radical cystectomy. Importantly, this study also demonstrated that longer duration of PAP incurred higher costs and was associated with an increased rate of C. difficile colitis. A small, prospective, non-randomized study showed equal efficacy of short-term PAP in preventing postoperative infections in patients undergoing radical cystectomy with ileum conduit compared to extended PAP. Nonetheless, larger randomized clinical trials supporting these findings are lacking.

The unwarranted extended use of antibiotics is a major concern as exposure to antibiotics is a driving force for the development of (multi-) resistant bacteria and will lead to an increasing number of difficult-to-treat infections. This has been recognized on both national and international levels and is addressed within antimicrobial stewardship frameworks.

This study will compare current practice (>48h PAP, "extended PAP") with the guideline recommended approach (24h PAP, "short term PAP") in a single-centre, prospective, randomised clinical non-inferiority trial. The primary outcome is the rate of SSI within 90 days post surgery. The aim of the study is to generate currently lacking evidence allowing for an optimised PAP strategy in a challenging surgical setting.

02

Conditions studied

  • Radical Cystectomy
  • Surgical Site Infection
  • Urologic Cancer
  • Perioperative/Postoperative Complications
  • Antibiotic Resistant Infection
  • Antibiotic Side Effect
  • Antibiotic-associated Diarrhea
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Written informed consent
  • Age >18 years
  • Planned radical cystectomy at the Department of Urology, Bern University Hospital

Exclusion criteria

Exclusion Criteria:

  • Contraindications to the classes of drugs under study, e.g. known hypersensitivity or allergy to class of drugs including alternatives described in the protocol or the investigational product,
  • Women who are pregnant or breast feeding (exclusion for surgery),
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Short PAP

    Perioperative antibiotic prophylaxis will be stopped after 24h

    Other: Short PAP

  • Active comparator
    Extended PAP

    Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)

    Other: Extended PAP

Interventions

  • OtherShort PAP

    Perioperative antibiotic prophylaxis for 24h

  • OtherExtended PAP

    Perioperative antibiotic prophylaxis for \>48h

05

What researchers measure

Primary outcomes

  1. Rate of Surgical Site infections (SSI)

    Rate of surgical site infections occurring within 90 days post surgery will be calculated for each patient.

    Time frame: 90 days

  2. Time to event of SSI

    Time to event of SSI (event free survival analysis)

    Time frame: 90 days

  3. Rate of Urinary tract infections (UTI)

    Rate of urinary tract infections occurring within 90 days post surgery will be calculated for each patient.

    Time frame: 90 days

  4. Time to event of UTI

    Time to event of UTI (event free survival analysis)

    Time frame: 90 days

Secondary outcomes

  1. Rate and type of Antibiotic associated adverse events (AEs)

    Rates and types of antibiotic associated AEs occurring within 30 days post surgery (direct AEs such as hypersensitivity reaction, hepatotoxicity, renal toxicity etc and indirect AEs such as line associated infections, C.difficile diarrhoea) will be assessed for each patient.

    Time frame: 30 days

  2. Frequency of multi-drug-resistant bacteria in urinary samples

    The frequency of multi-drug-resistant bacteria in urine samples obtained at predefined time points during the first 30 days post surgery will be calculated for each patient

    Time frame: 30 days

  3. Changes in fecal flora

    Changes in the composition of the fecal flora will be assessed in fecal samples collected at pre-specified time points

    Time frame: 30 days

  4. Antibiotic associated costs

    Directly antibiotic associated costs incurred during 30days post surgery will be assessed

    Time frame: 30 days

06

Study locations

2 sites
  • Department of Infectious Diseases, University Hospital Bern
    Bern, 3010, Switzerland
  • Department of Urology, University Hopspital Bern
    Bern, 3010, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03305627
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Responsible party
Sponsor
First posted
Oct 10, 2017
Start date
Apr 9, 2018
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Last update
May 8, 2024

Study contacts

Maria C Thurnheer, MD
principal investigator · Department of Infectious Diseases, University Hospital Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion